BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Dilon Diagnostics Release: BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts


7/11/2012 11:22:08 AM

NEWPORT NEWS, Va., July 10, 2012 /PRNewswire/ -- According to a new study by Korean researchers at the Ewha Women's Hospital in Seoul, published this year in the Annals of Nuclear Medicine, Molecular Breast Imaging (MBI), also known as BSGI, may be a better choice than MRI for women who have a new cancer diagnosis and dense breast tissue detected by mammography. According to their results, MBI/BSGI and MRI had nearly the same sensitivity for the detection of additional malignant tumors, but MBI/BSGI was much less likely to be positive in benign lesions.

In their work, Dr. Kim and his colleagues evaluated 66 patients who had a new breast cancer diagnosis and a reported mammography breast density of greater than 50% with MBI/BSGI and MRI prior to surgery. Both MBI/BSGI and MRI detected disease not seen by mammography, however, the MBI/BSGI was more accurate than MRI in determining if lesions were benign or malignant. Only 26% of the additional lesions detected by MRI were malignant compared to MBI/BSGI where 76% of the lesions detected were malignant. This is important for the newly diagnosed breast cancer patient since biopsy is required when imaging studies are positive. Therefore, MBI/BSGI could have led to a large decrease in the number of unnecessary biopsies for women in this trial. According to Dr. Kim, "The results of this study suggest that MBI/BSGI could play a crucial role as an adjunctive imaging modality which can be used to evaluate breast cancer patients with dense breasts."

About Dilon Diagnostics

Dilon Diagnostics®, a brand of Dilon Technologies® Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view gamma camera, optimized to perform MBI/BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering MBI/BSGI to their patients, such as Cornell University Medical Center, New York and George Washington University Medical Center, Washington, D.C. As part of Dilon's commitment to offering complete solutions, the new declipseSPECT is the first intra-operative handheld 3D image viewing and navigation solution with applications in SLNB breast, I-125 Seed Localization, SLNB Head and Neck etc. For more information on Dilon Technologies® please visit www.molecularbreastimaging.com

Media contact: Pjerin Luli
P: 757-269-4910
E: pluli@dilon.com

SOURCE Dilon Diagnostics


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->